Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Agilent Navigates Market Challenges: Q3 Exceeds Expectations As Strategic Investments Pay Off

Author: Lekha Gupta | August 22, 2024 09:44am

Agilent Technologies, Inc. (NYSE:A) shares are trading higher after the company reported third-quarter results yesterday.

Revenue fell 5.6% Y/Y to $1.58 billion, beating the consensus of $1.56 billion. By segment, the Life Sciences and Applied Markets Group (LSAG) segment reported revenue of $782 million, down 8% Y/Y (-7% Y/Y core), with an operating margin of 28.4%.

The Agilent CrossLab Group (ACG) revenue came in at $411 million, up 4% Y/Y (+5% Y/Y core), with an operating margin of 34.0%.

The Diagnostics and Genomics Group (DGG) revenue stood at $385 million, down 9% Y/Y (-8% Y/Y core), with an operating margin of 18.3%.

As of July 31, cash and cash equivalents stood at $1.78 billion. Adjusted EPS of $1.32 surpassed the street view of $1.26.

Outlook: Agilent forecasts fourth-quarter revenue of $1.641 billion – $1.691 billion (vs. $1.67 billion estimate) and adjusted EPS of $1.38 – $1.42 (vs. street view of $1.44).

For FY24, Agilent revised its revenue outlook to $6.45 billion – $6.5 billion from $6.42 billion – $6.5 billion (vs. $6.46 billion estimate) and adjusted EPS to $5.21 – $5.25 (vs. $5.20 estimate) from $5.15 – $5.25 earlier.

Agilent President and CEO Padraig McDonnell said, “While market conditions continued to be challenged during the quarter, we saw steady signs of improvement as anticipated. We continue to make investments in our most promising growth opportunities.”

“And we are mobilizing the organization to accelerate value creation through strategic transformation initiatives, which will drive margin expansion and growth—and increase our execution capabilities.”

Investors can gain exposure to the stock via ProShares Nanotechnology ETF (NYSE:TINY) and VanEck ETF Trust VanEck Morningstar Wide Moat Growth ETF (BATS:MGRO).

Price Action: A shares are up 1.88% at $142.63 at the last check Thursday.

Image from Shutterstock

Read Next:

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Posted In: A MGRO TINY

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist